Abstract
Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used for objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 who received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 19-22 |
Number of pages | 4 |
Journal | Cancer |
Volume | 42 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1978 |
ASJC Scopus subject areas
- Oncology
- Cancer Research